Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Loading
Home›
Research›
Investment Firms›
HealthCare Royalty Partners
AddedFeb 13, 2024
UpdatedJun 28, 2026
HealthCare Royalty Partners

HealthCare Royalty Partners

Operating

HealthCare Royalty Partners: A global private equity firm investing in healthcare and biotech royalties.

Location
Stamford, CT, US
Founded
2007
Firm
Compare
Portfolio
Fundraising
Employees

Investments

Liquidia
Liquidia
Public

Total Raised

$415.9M

Rounds

20

Post Ipo Debt$25MJanuary 2024
Post Ipo Debt$32.5MJanuary 2023
Cara Therapeutics
Cara Therapeutics
Public

Total Raised

$517.2M

Rounds

11

Post Ipo Debt$40MNovember 2023
Clearside Biomedical
Clearside Biomedical
Public

Total Raised

$188.9M

Rounds

8

Post Ipo Debt$65MAugust 2022
Ardelyx
Ardelyx
Public

Total Raised

$471.4M

Rounds

10

Public$20MJune 2022
Rhythm Pharmaceuticals
Rhythm Pharmaceuticals
Public

Total Raised

$895.5M

Rounds

11

Post Ipo Debt$37.5MJune 2022
Spero Therapeutics
Spero Therapeutics
Public

Total Raised

$443.6M

Rounds

16

Public$125MSeptember 2021
Coherus BioSciences
Coherus BioSciences
Public

Total Raised

$1.3B

Rounds

17

Post Ipo Debt$75MJanuary 2019
Helomics
Helomics

Total Raised

$211.5M

Rounds

11

Series E$60MNovember 2014
AcuFocus
AcuFocus
Acquired

Total Raised

$241.6M

Rounds

13

Series G$21MSeptember 2014
Private Equity$65MNovember 2011
Nuron Biotech
Nuron Biotech

Total Raised

$102.7M

Rounds

2

Private Equity$22.7MFebruary 2014
Private Equity$80MDecember 2012
Suneva Medical
Suneva Medical
Public

Total Raised

$175.7M

Rounds

10

Series B$20MJanuary 2014
Debt Financing$15MJanuary 2014